Tags

Type your tag names separated by a space and hit enter

Legal issues regarding gene editing at the beginning of life: an EU perspective.
Regen Med. 2017 09; 12(6):669-679.RM

Abstract

The development of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas gene-modification technologies has opened impressive possibilities for the biomedical sciences. However, their application to human embryos and early fetuses has raised huge ethical and legal discussions because it affects the human germline. This paper provides a critical and in-depth analysis of the current legal framework on this topic in the EU context and at the national level in the member states. It also offers an alternative interpretation of the regulation, so as to help researchers, practitioners, policy makers and society as a whole to find efficient responses to challenges that cannot wait for a legally updated answer. As a final result, this paper will show that eugenic uses of CRISP-Cas and any kind of modification intended to alter the human germ line are generally banned in the EU context, while basic research on human embryos is mostly permitted. The legal status of therapeutic applications of CRISPR-Cas on early fetuses, however, has not been adequately addressed by the EU zone regulation.

Authors+Show Affiliations

Cátedra de Derecho y Genoma Humano, Universidad Del País Vasco UPV/EHU, Bilbao, Spain.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28976851

Citation

De Miguel Beriain, Iñigo. "Legal Issues Regarding Gene Editing at the Beginning of Life: an EU Perspective." Regenerative Medicine, vol. 12, no. 6, 2017, pp. 669-679.
De Miguel Beriain I. Legal issues regarding gene editing at the beginning of life: an EU perspective. Regen Med. 2017;12(6):669-679.
De Miguel Beriain, I. (2017). Legal issues regarding gene editing at the beginning of life: an EU perspective. Regenerative Medicine, 12(6), 669-679. https://doi.org/10.2217/rme-2017-0033
De Miguel Beriain I. Legal Issues Regarding Gene Editing at the Beginning of Life: an EU Perspective. Regen Med. 2017;12(6):669-679. PubMed PMID: 28976851.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Legal issues regarding gene editing at the beginning of life: an EU perspective. A1 - De Miguel Beriain,Iñigo, Y1 - 2017/10/04/ PY - 2017/10/5/pubmed PY - 2018/7/4/medline PY - 2017/10/5/entrez KW - bioethics KW - biolaw KW - ethical KW - eugenics KW - gene editing KW - germline KW - human embryos KW - legal/regulatory KW - regulation SP - 669 EP - 679 JF - Regenerative medicine JO - Regen Med VL - 12 IS - 6 N2 - The development of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas gene-modification technologies has opened impressive possibilities for the biomedical sciences. However, their application to human embryos and early fetuses has raised huge ethical and legal discussions because it affects the human germline. This paper provides a critical and in-depth analysis of the current legal framework on this topic in the EU context and at the national level in the member states. It also offers an alternative interpretation of the regulation, so as to help researchers, practitioners, policy makers and society as a whole to find efficient responses to challenges that cannot wait for a legally updated answer. As a final result, this paper will show that eugenic uses of CRISP-Cas and any kind of modification intended to alter the human germ line are generally banned in the EU context, while basic research on human embryos is mostly permitted. The legal status of therapeutic applications of CRISPR-Cas on early fetuses, however, has not been adequately addressed by the EU zone regulation. SN - 1746-076X UR - https://www.unboundmedicine.com/medline/citation/28976851/Legal_issues_regarding_gene_editing_at_the_beginning_of_life:_an_EU_perspective_ L2 - http://www.futuremedicine.com/doi/full/10.2217/rme-2017-0033?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.